http://jco.ascopubs.org/content/early/2012/08/26/JCO.2012.43.6931.full.pdf+html
Overall, bevacizumab increases the risk of grade 3 to 5 AEs and SAEs without
apparent effect on OS and only moderate impact on PFS (Fig 1).
ということで、早く、biomarkerが分かるといいです。
さらに、
Although we, as a society, are committed to investing heavily in valuable treatments
against cancer, that investment is not a blank check, and a serious discussion among
all stakeholders is needed regarding the appropriate balance of costs and
effectiveness of treatments for advanced cancer.
とても大事なことだと思います。
